Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neil Thierry

Child & Adolescent Psychiatry Tampa, FL Medical Doctor

NPI 1548271596 CMS profile 160255

12512 Bruce B Downs Blvd, Tampa, FL 33612

Open in the dashboard

General payments

$3,710

242 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Neil Thierry of Tampa, FL is reported in the CMS Open Payments database as having received $3,710 across 242 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,850 108
2024 General $772 45
2023 General $497 44
2022 General $231 31
2021 General $227 12
2019 General $133 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neil Thierry
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Neil Thierry were reported at $1,850. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Neil Thierry Child & Adolescent Psychiatry median Middle half National median
2019 $133 $129 $42–$419 $163
2020 $0 $81 $28–$226 $114
2021 $227 $115 $31–$326 $132
2022 $231 $124 $40–$382 $149
2023 $497 $130 $45–$420 $160
2024 $772 $141 $42–$490 $164
2025 $1,850 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ironshore Pharmaceuticals Inc. $830 76 payments
  2. Teva Pharmaceuticals USA, Inc. $473 40 payments
  3. Alkermes, Inc. $416 25 payments
  4. ITI, Inc. $334 16 payments
  5. Neurocrine Biosciences, Inc. $298 12 payments
  6. Otsuka America Pharmaceutical, Inc. $295 19 payments
  7. E.R. Squibb & Sons, L.L.C. $240 12 payments
  8. AbbVie, Inc. $226 16 payments
  9. Janssen Pharmaceuticals, Inc $188 8 payments
  10. Tris Pharma Inc $144 3 payments
  11. Other $266 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,710 242 payments
Products named General payments · program years 2019–2025
  1. JORNAY PM Central Nervous Stimulant ADHD $458 43 payments
  2. LYBALVI $398 24 payments
  3. INGREZZA $298 12 payments
  4. ARISTADA Cns $275 17 payments
  5. ARISTADA Cns $275 17 payments
  6. ARISTADA Cns $275 17 payments
  7. ARISTADA Cns $275 17 payments
  8. UZEDY $261 19 payments
  9. JORNAY PM Central Nervous System Stimulant $250 32 payments
  10. COBENFY $191 10 payments
  11. Other $2,522 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

201

Median for Psychiatry: 574

Drug cost

$3,060

Median for Psychiatry: $27,624

Branded share of claims

12.9%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aripiprazole Generic 15 $607
Benztropine Mesylate Generic 24 $470
Hydroxyzine Pamoate Generic 19 $361
Risperidone Generic 18 $278
Haloperidol Generic 17 $271
Quetiapine Fumarate Generic 15 $239
Lurasidone Hcl Generic 13 $217
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 12 $157
Bupropion Xl Bupropion Hcl Brand 14 $145
Sertraline Hcl Generic 18 $138

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UZEDY
  • Teva Pharmaceuticals USA, Inc. $90
$90 — —
CAPLYTA
  • ITI, Inc. $73
$73 — —
PERSERIS
  • Indivior Inc. $72
$72 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $71
$71 — —
VRAYLAR
  • AbbVie, Inc. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

242 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record